A novel GIP-Oxyntomodulin hybrid peptide acting through GIP, glucagon and GLP-1 receptors exhibits weight reducing and anti-diabetic properties.

VK Bhat, BD Kerr, Peter Flatt, Victor Gault

Research output: Contribution to journalArticlepeer-review

55 Citations (Scopus)

Fingerprint

Dive into the research topics of 'A novel GIP-Oxyntomodulin hybrid peptide acting through GIP, glucagon and GLP-1 receptors exhibits weight reducing and anti-diabetic properties.'. Together they form a unique fingerprint.

Medicine & Life Sciences

Chemical Compounds